Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
3 studies found for:    3334893 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting ESHAP-Imatinib for Refractory/Relapsed Non-Hodgkin's Lymphoma
Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: ESHAP-Imatinib
2 Active, not recruiting Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment
Conditions: Lymphoma, Non-Hodgkin;   Advanced Stage Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Interventions: Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone;   Drug: Ondansetron;   Drug: Dexamethasone;   Drug: Diphenhydramine;   Drug: Acetaminophen;   Drug: Ifosfamide;   Drug: Mesna (IV);   Drug: Mesna (oral);   Drug: Carboplatin;   Drug: Etoposide;   Drug: Rituximab;   Other: PET Scan
3 Completed Humanized LL2IGG to Treat Systemic Lupus Erythematosus
Condition: Systemic Lupus Erythematosus
Intervention: Drug: hLL2 (Epratuzumab)

Indicates status has not been verified in more than two years